Key points from article :
Magnitude Biosciences provides specialist C. elegans research services to the longevity, nutraceuticals and pharmaceutical industries.
Investment of £500,000 will be made by North East (ERDF) Innovation Fund Limited Partnership.
Funding will enable expansion of its research facilities and automation of key processes.
Output from experiments can be provided in as little as 2 weeks and provide a wealth of experimental data.
The investment follows the appointment of Dr Fozia Saleem as CEO in October 2022.
She commented that ‘using C. elegans to screen compounds ... is becoming recognised ... as a more ethical, less expensive, and faster means of generating in vivo preclinical data to support lead selection.'
Magnitude Biosciences’ Chair, Dr Sally Waterman, said: ‘This further investment ... will enable us to increase our capacity to work with companies who are developing new therapies and health supplements which could help us have a longer and healthier life."
